分子标志物评估显示立体定向活检与开颅手术获取的样本在间变性星形细胞瘤和胶质母细胞瘤中具有一致性
研究纳入2009至2013年22例经立体定向活检诊断为高级别胶质瘤后接受开颅手术的患者,前瞻性比较活检与开颅样本的MGMT启动子甲基化和IDH1R132H突变。除1例MGMT结果不一致外,组织学分级、IDH1R132H和MGMT结果均一致,提示临床决策可基于立体定向活检样本的分子特征。
要点
- 22例高级别胶质瘤患者中,3例(13.7%)活检样本检出IDH1R132H突变。
- 活检样本MGMT启动子甲基化10例(45.5%),非甲基化10例(45.5%),不确定2例(9%)。
- 除1例MGMT结果不一致外,开颅样本证实了活检的组织学分级、IDH1R132H和MGMT结果。
核心结论
- 立体定向活检样本可提供与临床相关的分子标志物准确信息,其标志物谱与开颅样本几乎一致,提示临床决策可基于立体定向活检样本的分子特征。
研究设计与样本
- 2009年至2013年前瞻性纳入22例经立体定向活检初步诊断为高级别胶质瘤、最终接受开颅肿瘤切除的患者,纳入机构胶质瘤数据库。
- MGMT启动子分析采用甲基化特异性PCR(MS-PCR),IDH1R132H突变分析采用免疫组化。
主要发现
- 3例患者(13.7%)经立体定向活检获得的样本检出IDH1R132H突变。
- 立体定向活检组织显示MGMT启动子甲基化10例(45.5%),非甲基化10例(45.5%),不确定2例(9%)。
- 除1例患者外,开颅手术样本证实了初始组织学分级、IDH1R132H突变和MGMT启动子甲基化结果;该例开颅样本MGMT分析不确定,与立体定向活检结果相反。
关键数值与推荐
- MGMT启动子甲基化:活检样本甲基化10例(45.5%)、非甲基化10例(45.5%)、不确定2例(9%)。
- IDH1R132H突变:活检样本检出3例(13.7%)。
临床怎么用
- 作者认为,临床决策可基于立体定向活检所得肿瘤样本的分子特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The classification, treatment and prognosis of high-grade gliomas has been shown to correlate with the expression of molecular markers (e.g. MGMT promotor methylation and IDH1 mutations). Acquisition of tumor samples may be obtained via stereotactic biopsy or open craniotomy. Between the years 2009 and 2013, 22 patients initially diagnosed with HGGs via stereotactic biopsy, that ultimately underwent open craniotomy for resection of their tumor were prospectively included in an institutional glioma database. MGMT promotor analysis was performed using methylation-specific (MS)-PCR and IDH1R132H mutation analysis was performed using immunohistochemistry. Three patients (13.7%) exhibited IDH1R132H mutations in samples obtained via stereotactic biopsy. Tissue derived from stereotaxic biopsy was demonstrated to have MGMT promotor methylation in ten patients (45.5%), while a non-methylated MGMT promotor was demonstrated in ten patients (45.5%); inconclusive results were obtained for the remaining two patients (9%) within our cohort. The initial histologic grading, IDH1R132H mutation and MGMT promotor methylation results were confirmed using samples obtained during open craniotomy in all but one patient; here inconclusive MGMT promotor analysis was obtained in contrast to that which was obtained via stereotactic biopsy. Tumor samples acquired via stereotactic biopsy provide accurate information with regard to clinically relevant molecular markers that have been shown to impact patient care decisions. The profile of markers analyzed in our cohort was nearly concordant between those samples obtained via stereotactic biopsy or open craniotomy thereby suggesting that clinical decisions may be based on the molecular profile of the tumor samples obtained via stereotactic biopsy.
引用
- Gessler F, Baumgarten P, Bernstock JD, et al. Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas. J Neurooncol. 2017. PMID: 28508327. doi:10.1007/s11060-017-2448-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。